Search results for " Myocardial"

showing 10 items of 305 documents

Circulating miRNA Fingerprint and Endothelial Function in Myocardial Infarction: Comparison at Acute Event and One-Year Follow-Up.

2022

MicroRNAs (miRNA) are major regulators of intercellular communication and key players in the pathophysiology of cardiovascular disease. This study aimed to determine the miRNA fingerprint in a cohort of 53 patients with acute myocardial infarction (AMI) with non-ST-segment elevation (NSTEMI) relative to miRNA expression in healthy controls (n = 51). miRNA expression was initially profiled by miRNA array in the serum of patients undergoing cardiac catheterization during NSTEMI (n = 8) and 1 year past the event (follow-up, n = 8) and validated in the entire cohort. In total, 58 miRNAs were differentially expressed during AMI (p < 0.05), while 36 were modified at follow-up (Fisher’s exact t…

Fisiologia cel·lularMicroRNAsMyocardial InfarctionmicroRNA profile; serum biomarker; myocardial infarction; endothelial cell; let-7e; angiogenesisCytokinesEndothelial CellsHumansGeneral MedicineCirculating MicroRNAMalalties coronàriesNon-ST Elevated Myocardial InfarctionFollow-Up StudiesCells
researchProduct

Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice

2002

The serine-threonine kinase Akt seems to be central in mediating stimuli from different classes of receptors. In fact, both IGF-1 and IL6-like cytokines induce hypertrophic and antiapoptotic signals in cardiomyocytes through PI3K-dependent Akt activation. More recently, it was shown that Akt is involved also in the hypertrophic and antiapoptotic effects of β-adrenergic stimulation. Thus, to determine the effects of Akt on cardiac function in vivo, we generated a model of cardiac-specific Akt overexpression in mice. Transgenic mice were generated by using the E40K, constitutively active mutant of Akt linked to the rat α-myosin heavy chain promoter. The effects of cardiac-selective Akt overex…

Gene ExpressionTransgenicGlycogen Synthase Kinase 3MiceGSK-3Receptorsgenetics/physiologycytology/metabolismMultidisciplinaryBiological SciencesProtein-Serine-Threonine KinasesDNA-Binding Proteinsenzymology/genetics/pathologyAdrenergicPhosphorylationSignal transductionMitogen-Activated Protein KinasesSignal Transductionmedicine.medical_specialtyCardiomyopathyAnimals; Calcium-Calmodulin-Dependent Protein Kinases; metabolism; Cardiomyopathy; Hypertrophic; enzymology/genetics/pathology; Cell Size; physiology; DNA-Binding Proteins; GATA4 Transcription Factor; Gene Expression; Glycogen Synthase Kinase 3; Mice; Transgenic; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; cytology/metabolism; Point Mutation; Protein-Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins; genetics/physiology; Rats; Receptors; Adrenergic; beta; Signal Transduction; Transcription FactorsMice TransgenicBiologyProtein Serine-Threonine KinasesContractilityIn vivoInternal medicineProto-Oncogene ProteinsReceptors Adrenergic betamedicineAnimalsPoint MutationGlycogen synthaseProtein kinase BPI3K/AKT/mTOR pathwayCell SizeMyocardiumCardiomyopathy HypertrophicMyocardial ContractionGATA4 Transcription FactorRatsEndocrinologyHypertrophicphysiologyCalcium-Calmodulin-Dependent Protein Kinasesbiology.proteinbetametabolismProto-Oncogene Proteins c-aktTranscription Factors
researchProduct

Mediterranean diet adherence and synergy with acute myocardial infarction and its determinants: A multicenter case-control study in Italy

2018

Background Cardiovascular diseases are the leading causes of mortality and morbidity in Western countries. The possible synergistic effect of poor adherence to a Mediterranean diet (MD) and other risk factors for acute myocardial infarction (AMI) such as hypertension, cholesterol, ever smoker, BMI> 25, diabetes, has not been deeply studied. Design Case-control study. Methods Patients with first AMI and controls from four tertiary referral Italian centers were screened for enrolment. Dietary information was collected through a questionnaire and a MD adherence score was calculated. Physical activity and smoking habits were also registered. The Synergy Index was calculated according to Rothman…

Genetics and Molecular Biology (all)MaleMultivariate analysisMediterranean dietTertiary Care CenterMyocardial Infarctionlcsh:MedicineBlood PressureMediterranean030204 cardiovascular system & hematologyPathology and Laboratory MedicineDiet MediterraneanVascular MedicineBiochemistryGeographical locationsTertiary Care CentersHabitschemistry.chemical_compoundEndocrinology0302 clinical medicineRisk FactorsSurveys and QuestionnairesMedicine and Health SciencesSmoking HabitsSurveys and Questionnaire030212 general & internal medicineMyocardial infarctionlcsh:ScienceMultidisciplinarySmokingMiddle AgedEuropeHyperlipidemiaItalyResearch DesignSettore MED/42HypertensionFemaleCase-Control StudieHumanResearch Articlemedicine.medical_specialtyAged; Case-Control Studies; Feeding Behavior; Female; Humans; Hypertension; Italy; Male; Middle Aged; Myocardial Infarction; Risk Factors; Smoking; Surveys and Questionnaires; Tertiary Care Centers; Diet Mediterranean; Patient ComplianceReferralEndocrine DisordersSmoking habitHypercholesterolemiaCardiologyResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDiagnostic MedicineDiabetes mellitusInternal medicineDiabetes MellitusAged; Case-Control Studies; Feeding Behavior; Female; Humans; Hypertension; Italy; Male; Middle Aged; Myocardial Infarction; Risk Factors; Smoking; Surveys and Questionnaires; Tertiary Care Centers; Diet Mediterranean; Patient Compliance; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)medicineHumansEuropean UnionNutritionAgedBehaviorCholesterolbusiness.industryRisk Factorlcsh:RCase-control studyBiology and Life SciencesFeeding Behaviormedicine.diseaseDietAgricultural and Biological Sciences (all)chemistryMetabolic DisordersCase-Control StudiesPatient Compliancelcsh:QPeople and placesbusinessPLOS ONE
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

The Interplay between Child Maltreatment and Stressful Life Events during Adulthood and Cardiovascular Problems—A Representative Study

2021

Psychological stress is a major risk factor for cardiovascular diseases. While the relevance of early life stress, such as that which is due to child maltreatment (CM), is well known to impact individual stress responses in the long-term, and data on the interplay between CM and stressful events in adulthood on cardiovascular health are sparse. Here, we aimed to assess how stressful life events in adulthood are associated with cardiovascular health infarction in later life and whether this association is independent of CM. In a cross-sectional design, a probability sample of the German population above the age of 14 was drawn using different sampling steps. The final sample included 2510 pe…

Gerontologyobesityhypertensionstressful life eventsInfarctionStressArticleOddsDiabetes mellitusDiabetes mellitusmedicineHypertonieddc:610ObesityRisk factorChild maltreatmentchild maltreatment; stressful life events; cardiovascular problems; obesity; diabetes; hypertension; myocardial infarctionStress (Psychology)diabetesbusiness.industryStressorRGeneral MedicineOdds ratiomedicine.diseaseObesityMyocardial infarctionmyocardial infarctionCardiovascular diseasesHerzinfarktFettsuchtcardiovascular problemsHypertensionKindesmisshandlungMedicinebusinessPsychosocialDDC 610 / Medicine & healthHerzkrankheitchild maltreatmentStress PsychologicalChild abuseJournal of Clinical Medicine
researchProduct

Early cardiac unloading with ImpellaCP™ in acute myocardial infarction with ventricular septal defect

2020

Abstract Despite a relative contraindication, mechanical support with Impella™ left ventricular assist device has already been described for ischaemic ventricular septal defect treatment, either as a bridge to surgery, as intraoperative mechanical haemodynamic support, or to ensure intraprocedural haemodynamic stability during device closure. We describe two cases of ventricular septal defect complicating acute myocardial infarction, where the percutaneous ImpellaCP was implanted early (differently than previously described) with the aim of preventing haemodynamic instability, while deferring surgical repair. We present a report of haemodynamic, echocardiographic, biochemical, and clinical …

Heart Septal Defects Ventricularmedicine.medical_specialtyPercutaneousAcute myocardial infarction mechanical complicationmedicine.medical_treatmentMyocardial InfarctionCase ReportLeft ventricular assist device610 Medicine & health030204 cardiovascular system & hematologyVentricular septal defectImpella11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineHumans030212 general & internal medicineMyocardial infarctioncardiovascular diseasesContraindicationImpellaSurgical repairbusiness.industryHemodynamicsAcute heart failureHeartPerioperativemedicine.diseaseRC666-701Heart failureVentricular assist deviceCardiologyHeart-Assist DevicesCardiology and Cardiovascular Medicinebusiness
researchProduct

Epidemiological approach of type 2 myocardial infarction : Etiologies, characteristics, treatment and prognosis.

2020

Introduction: Type 2 Myocardial infarction (MI)has been recently defined as an imbalance between oxygen supply and demand, in the absence of atherothromthrombosis. This work aimed to describe the main etiolgies as well as epidemiological, clinical and prognostic characteristics.Method: Data from patients with type 2 MI were collected from the RICO cohort (Observatoire des Infarctus de Cote d'Or). In a complementary work, we analyzed the retrospective data of the emergency department of Dijon University Hospital.Results: Among 4,436 consecutive patients hospitalized for MI in Dijon emergency department over 3 years, 947 (21%) had type 2 MI (median age: 81 years). In the RICO cohort, 4,572 co…

Infactus du myocardeÉpidémiologieMyocardial infarctionEtiologies[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyÉtiologiesEpidemiologyTyoe 2 myocardial infarctionInfarctus de type 2PronosticPrognosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: No eviden…

2003

Abstract The release of choline as a water-soluble product of phospholipid hydrolysis was measured in the perfusate of rat hearts to monitor ischemic membrane degradation and its protection by ischemic preconditioning (IPC). Hearts were subjected to global ischemia (GI; 30 min of no-flow) followed by 60 min of reperfusion. To induce IPC, GI was preceded by four no-flow episodes of 5 min each. Deleterious consequences of GI and reperfusion, namely coronary flow reduction, incidence of arrhythmias and release of cardiac troponin T, were significantly attenuated by IPC. The release of choline increased during reperfusion in a biphasic manner: a first phase peaked immediately after GI and was f…

IschemiaPhospholipid610 Medicine & healthArachidonic AcidsPharmacologyPhospholipasePhospholipases AGeneral Biochemistry Genetics and Molecular Biology3000 General Pharmacology Toxicology and PharmaceuticsCholineRats Sprague-Dawleychemistry.chemical_compoundTroponin T1300 General Biochemistry Genetics and Molecular Biologyparasitic diseasesPhospholipase DmedicineAnimalsCholinecardiovascular diseasesGeneral Pharmacology Toxicology and PharmaceuticsPhospholipidsPhospholipase APhospholipase DMyocardiumGeneral Medicinemedicine.diseaseRatsPhospholipases A2CytosolchemistryBiochemistry10054 Clinic for Psychiatry Psychotherapy and PsychosomaticsIschemic Preconditioning MyocardialIschemic preconditioninghuman activities
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

2012

BACKGROUND: High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent of non-genetic confounding, and are unmodified by disease processes, mendelian randomisation can be used to test the hypothesis that the association of a plasma biomarker with disease is causal. METHODS: We performed two mendelian randomisation analyses. First, we used as an instrument a single nucleotide polymorphism (SNP) in the endothelial lipase gene (LIPG Asn396Ser) and tested this SNP in 20 studies (20,913 myocardial infarction cases, 95,407 controls). Se…

LOCIMyocardial Infarction030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinGene Frequencyplasma HDL cholesterol ; mendelian randomisation ; MIHDL cholesterolsingle nucleotide polymorphismRisk FactorsGENETIC-VARIANTSARTERY-DISEASEProspective StudiesMyocardial infarction0303 health sciencesHDL cholesterol; myocardial infarction; single nucleotide polymorphismISCHEMIC CARDIOVASCULAR-DISEASEGeneral Medicine3. Good healthCardiologylipids (amino acids peptides and proteins)medicine.medical_specialtyDalcetrapibSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineHumansCORONARY-HEART-DISEASEGenetic Predisposition to DiseaseMETAANALYSIS030304 developmental biologyBLOOD CHOLESTEROLbusiness.industryCholesterolCholesterol HDLCase-control studyCholesterol LDLLipaseOdds ratioMendelian Randomization Analysismedicine.diseaseENDOTHELIAL LIPASEATHEROSCLEROSISchemistryCase-Control StudiesbusinessHIGH-DENSITY-LIPOPROTEINBiomarkersEvacetrapibThe Lancet
researchProduct